
Danaher Corp (DHR)
NEW YORK STOCK EXCHANGE, INC. · Life Sciences Tools & Services
Consenso analisti
Cosa significano questi rating?32 analisti: 12 Strong Buy · 15 Buy · 5 Hold · 0 Sell.
Target price analisti
Statistiche chiave
Fondamentali e dati di trading aggiornati. Fonte: Finnhub.
Notizie sul titolo
Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.
Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "TDM Reagent Kit Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion
Danaher (DHR) stays a hold: modest core growth and higher leverage after the Masimo acquisition limit upside despite synergies.
Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the
Biologics, stricter purity rules and flexible manufacturing are driving demand for single-use, automated and continuous filtration, advanced membranes and sustainable systems.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Filtration - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmaceutical Filtration was estimated at US$8.0 Billion in 2025 and is projected to reach US$23.4 Billion by 2032, growing at a CAGR of 16.7% f
Bioreactors Market Gains Momentum as Single-Use Systems, Automation and Advanced Therapies Reshape BiomanufacturingDublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Bioreactors Market to Reach USD 38.9 Billion by 2035 as Advanced Biomanufacturing Expands The global bioreactors market was valued at USD 13.8 billion in 2025 and is projected to reach
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.
Informazioni su Danaher Corp
Danaher Corp è quotata su NEW YORK STOCK EXCHANGE, INC. con il ticker DHR e opera nel settore Life Sciences Tools & Services. La capitalizzazione di mercato è di circa 158 miliardi di dollari.
Il consenso corrente degli analisti su DHR è Buy, calcolato su 32 giudizi: 12 Strong Buy, 15 Buy, 5 Hold, 0 Sell e 0 Strong Sell.
DHR tratta a un rapporto prezzo/utili (P/E) di 39,41. L'utile per azione degli ultimi dodici mesi è di 5,63 dollari. Il rendimento da dividendo è del 0,49%. Nelle ultime 52 settimane il titolo si è mosso tra 160,93 e 242,80 dollari.
Questa pagina raccoglie la quotazione in tempo reale di DHR, il grafico storico da 1 giorno a 5 anni, il target price medio degli analisti, i principali indicatori fondamentali (P/E, capitalizzazione, margini, crescita, indebitamento) e le ultime notizie sulla società. I prezzi sono consultabili in cinque valute.
Altri titoli Sanità e Farmaceutica →Cosa significano questi rating?
Solo scopo informativo. NON è consulenza finanziaria né raccomandazione di investimento (D.Lgs. 58/1998). I giudizi mostrati sono il consenso medio aggregato di analisti terzi via Finnhub. Vedi note legali. Note legali